バイデン政権のガイダンスは、COVID薬の投与において人種を優先します

fact sheet issued for healthcare providers by the Food and Drug Administration, the federal agency approved emergency use authorizations of sotrovimab – a monoclonal antibody proven to be effective against the Omicron variant – only to patients consideredhigh risk.

A vial of Regeneron monoclonal antibody sits on a medical table at the Sarasota Memorial Urgent Care Center in Sarasota, フロリダ, 我ら。, 9月 23, 2021.

A vial of Regeneron monoclonal antibody sits on a medical table at the Sarasota Memorial Urgent Care Center in Sarasota, フロリダ, 我ら。, 9月 23, 2021. (Reuters/Shannon Stapleton)

The guidance, updated in December 2021, 言う “medical conditions or factors” といった “人種または民族” have the potential toplace individual patients at high risk for progression to severe COVID-19,” 特別検察庁は、これらの申し立てに対する支持を確認していません “authorization of sotrovimab under the EUA is not limited toother factors outlined by the agency.

NEW YORK SAYS IT WILL PRIORITIZE NON-WHITE PEOPLE IN DISTRIBUTING LOW SUPPLY OF COVID-19 TREATMENTS

Older age, obesity, 妊娠, chronic kidney disease, diabetes, and cardiovascular disease are among the multiple medical conditions and factors associated with what are consideredhigh riskindividuals by the FDA.

Some states, including New York and Utah, have made it clear they will prioritize certain racial minorities over other highrisk patients when it comes to the distribution of particular COVID treatments.

先週, ニューヨーク’s Department of Health released a document detailing its plan to distribute treatments such as monoclonal antibody treatment and antiviral pills.

The plan includes a section on eligibility for the scarce antiviral pills that people must meet to receive the treatment, including a line stating a person needs to havea medical condition or other factors that increase their risk for severe illness.

File photo of a man receiving a shot in a doctor's office.

File photo of a man receiving a shot in a doctor’s office. (イチジク)

CALIFORNIA STUDENTS SUFFERED ACADEMICALLY DURING COVID-19, NEW REPORT REVEALS

One suchrisk factoris being a race or ethnicity that is not White due tolongstanding systemic health and social inequities.

Non-white race or Hispanic/Latino ethnicity should be considered a risk factor, as longstanding systemic health and social inequities have contributed to an increased risk of severe illness and death from COVID-19,the memo 読む.

ガイドライン issued by the state of Utah for the distribution of monoclonal antibodies in the state, residents who arenon-white race or Hispanic/Latinx ethnicityreceive 2 additional points when calculating theirCOVID-19 risk score.

Race/ethnicity continues to be a risk factor for severe COVID-19 disease, and the Utah COVID Risk Score is one approach to address equitable access to hard hit communities,” the Utah guidance stated, adding a reminder that national guidance from the FDAspecifically states that race and ethnicity may be considered when identifying patients most likely to benefit from this lifesaving treatment.

A healthcare worker attaches an IV infusion to a patient's hand during a monoclonal antibody treatment in the parking lot at Wayne Health Detroit Mack Health Center in Detroit, ミシガン, 我ら。, 木曜日に, 12月. 23, 2021.

A healthcare worker attaches an IV infusion to a patient’s hand during a monoclonal antibody treatment in the parking lot at Wayne Health Detroit Mack Health Center in Detroit, ミシガン, 我ら。, 木曜日に, 12月. 23, 2021. (Emily Elconin/Bloomberg via Getty Images)

同様に, the framework issued by the state of Minnesota advises clinicians and health systems toconsider heightened risk of progression to severe COVID-19 associated with race and ethnicity when determining eligibilityfor the allocation for monoclonal antibody therapies.

FDA’s acknowledgment means that race and ethnicity alone, apart from other underlying health conditions, may be considered in determining eligibility for mAbs,” the framework states. “It is ethically appropriate to consider race and ethnicity in mAb eligibility decisions when data show elevated risk of poor COVID-19 outcomes for Black, Indigenous and other people of color (BIPOC populations), and that this risk cannot be adequately addressed by determining eligibility based on underlying health conditions (perhaps due to underdiagnosis of health conditions that elevate risk of poor COVID-19 outcomes in these populations).”

フォックス・ニュース’ Houston Keene contributed to this article.

コメントは締め切りました.